Talipexole (B-HT920, Domnin) is a dopamine agonist that is marketed as a treatment for Parkinson's disease in Japan by Boehringer Ingelheim; it was introduced in 1996. As of December 2014 it was not approved for marketing in the US nor in Europe.
Talipexole (B-HT920, Domnin) is a dopamine agonist that is marketed as a treatment for Parkinson's disease in Japan by Boehringer Ingelheim; it was introduced in 1996. As of December 2014 it was not approved for marketing in the US nor in Europe.
Talipexole is a dopamine D2 receptor agonist and interacts with both pre- and post-synaptic receptors. It also is an α2-adrenergic agonist.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).